APRE Valuation

Aprea Therapeutics Inc

Add to Watchlist

Advanced Chart

1.580

-0.02(-1.250%)1D

Overview
Forecast
Valuation
Earnings

APRE Relative Valuation

APRE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, APRE is overvalued; if below, it's undervalued.

Historical Valuation

Aprea Therapeutics Inc (APRE) is now in the Fair zone, suggesting that its current forward PS ratio of 153.75 is considered Fairly compared with the five-year average of -1.45. The fair price of Aprea Therapeutics Inc (APRE) is between 0.41 to 1.61 according to relative valuation methord.

Relative Value

Fair Zone

0.41-1.61

Current Price：1.60

Fair

-1.02

Trailing

Forward

0.00

EV/EBITDA

Aprea Therapeutics Inc. (APRE) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.30. The thresholds are as follows: Strongly Undervalued below -0.59, Undervalued between -0.59 and -0.15, Fairly Valued between 0.75 and -0.15, Overvalued between 0.75 and 1.20, and Strongly Overvalued above 1.20. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.43

EV/EBIT

Aprea Therapeutics Inc. (APRE) has a current EV/EBIT of 0.43. The 5-year average EV/EBIT is 0.22. The thresholds are as follows: Strongly Undervalued below -1.08, Undervalued between -1.08 and -0.43, Fairly Valued between 0.88 and -0.43, Overvalued between 0.88 and 1.53, and Strongly Overvalued above 1.53. The current Forward EV/EBIT of 0.43 falls within the Historic Trend Line -Fairly Valued range.

153.75

Aprea Therapeutics Inc. (APRE) has a current PS of 153.75. The 5-year average PS is 59.41. The thresholds are as follows: Strongly Undervalued below -83.76, Undervalued between -83.76 and -12.17, Fairly Valued between 131.00 and -12.17, Overvalued between 131.00 and 202.59, and Strongly Overvalued above 202.59. The current Forward PS of 153.75 falls within the Overvalued range.

0.00

P/OCF

Aprea Therapeutics Inc. (APRE) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.08. The thresholds are as follows: Strongly Undervalued below -0.39, Undervalued between -0.39 and -0.23, Fairly Valued between 0.08 and -0.23, Overvalued between 0.08 and 0.24, and Strongly Overvalued above 0.24. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Aprea Therapeutics Inc. (APRE) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.36. The thresholds are as follows: Strongly Undervalued below -1.19, Undervalued between -1.19 and -0.78, Fairly Valued between 0.05 and -0.78, Overvalued between 0.05 and 0.46, and Strongly Overvalued above 0.46. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Aprea Therapeutics Inc (APRE) has a current Price-to-Book (P/B) ratio of 0.60. Compared to its 3-year average P/B ratio of 0.78 , the current P/B ratio is approximately -23.18% higher. Relative to its 5-year average P/B ratio of 0.68, the current P/B ratio is about -11.37% higher. Aprea Therapeutics Inc (APRE) has a Forward Free Cash Flow (FCF) yield of approximately -141.84%. Compared to its 3-year average FCF yield of -105.94%, the current FCF yield is approximately 33.89% lower. Relative to its 5-year average FCF yield of -110.86% , the current FCF yield is about 27.94% lower.

0.60

P/B

Median3y

0.78

Median5y

0.68

-141.84

FCF Yield

Median3y

-105.94

Median5y

-110.86

Competitors Valuation Multiple

The average P/S ratio for APRE's competitors is 150.30, providing a benchmark for relative valuation. Aprea Therapeutics Inc Corp (APRE) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -78.97%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

APRE.O

Aprea Therapeutics Inc

Dogwood Therapeutics Inc

Loss

9.54M

KPRX.O

Kiora Pharmaceuticals Inc

Bolt Biotherapeutics Inc

Performance Decomposition

Market capitalization of APRE decreased by 53.92% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -617.92 to -2.74K.

The secondary factor is the Revenue Growth, contributed -78.97%to the performance.

Overall, the performance of APRE in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-78.97%

561.57K → 118.11K

Revenue Growth

343.78%

-617.92 → -2.74K

Margin Expansion

-318.73%

0.33 → -0.72

P/E Change

-53.92%